Literature DB >> 12646737

Recurrence of symptoms after Chiari decompression and duraplasty with nonautologous graft material.

David S Rosen1, Robert Wollman, David M Frim.   

Abstract

Nonautologous material is commonly used for dural grafting. Although good results have been reported with the use of some of these materials in cranial surgery, there is a paucity of information regarding their use in craniocervical decompressive surgery. We report three cases of patients with Chiari malformation type I who experienced recurrent or new-onset Chiari symptoms after surgical decompression and duraplasty with bovine pericardium, Gore-Tex or cadaveric dura. We review the use of these materials and propose possible mechanisms by which a reaction to a nonautologous graft could cause recurrent Chiari symptoms. The preferential use of autologous material for dural grafts during posterior fossa decompressive surgery should prevent this cause of symptom recurrence. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646737     DOI: 10.1159/000069097

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  12 in total

1.  Autologous tissues for dural grafting in children: a report of 56 cases.

Authors:  Juan F Martínez-Lage; Miguel A Pérez-Espejo; Joaquín Hernández Palazón; Francisco López Hernández; Pablo Puerta
Journal:  Childs Nerv Syst       Date:  2005-09-27       Impact factor: 1.475

2.  Bony decompression vs duraplasty for Chiari I malformation: does the eternal dilemma matter?

Authors:  Luca Massimi; P Frassanito; F Bianchi; G Tamburrini; M Caldarelli
Journal:  Childs Nerv Syst       Date:  2019-06-18       Impact factor: 1.475

3.  International survey on the management of Chiari 1 malformation and syringomyelia: evolving worldwide opinions.

Authors:  Ash Singhal; Alexander Cheong; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2018-03-12       Impact factor: 1.475

4.  Comparison of dural grafts in Chiari decompression surgery: Review of the literature.

Authors:  Adib A Abla; Timothy Link; David Fusco; David A Wilson; Volker K H Sonntag
Journal:  J Craniovertebr Junction Spine       Date:  2010-01

5.  Suboccipital decompression for Chiari I malformation: outcome comparison of duraplasty with expanded polytetrafluoroethylene dural substitute versus pericranial autograft.

Authors:  Frank J Attenello; Matthew J McGirt; Giannina L Garcés-Ambrossi; Kaisorn L Chaichana; Benjamin Carson; George I Jallo
Journal:  Childs Nerv Syst       Date:  2008-09-04       Impact factor: 1.475

6.  Pseudomeningocele formation following chiari decompression: 19-year retrospective review of predisposing and prognostic factors.

Authors:  R Menger; D E Connor; M Hefner; G Caldito; A Nanda
Journal:  Surg Neurol Int       Date:  2015-05-07

7.  Two alternative dural sealing techniques in posterior fossa surgery: (Polylactide-co-glycolide) self-adhesive resorbable membrane versus polyethylene glycol hydrogel.

Authors:  Marco Schiariti; Francesco Acerbi; Morgan Broggi; Giovanni Tringali; Alberto Raggi; Giovanni Broggi; Paolo Ferroli
Journal:  Surg Neurol Int       Date:  2014-12-03

8.  The need in dural graft suturing in Chiari I malformation decompression: A prospective, single-blind, randomized trial comparing sutured and sutureless duraplasty materials.

Authors:  Leena E Williams; Prasad S Vannemreddy; Karriem S Watson; Konstantin V Slavin
Journal:  Surg Neurol Int       Date:  2013-02-27

9.  Fibrin sealant augmentation with autologous pericranium for duraplasty after suboccipital decompression in Chiari 1 patients: A case series.

Authors:  Fred C Lam; Anirudh Penumaka; Clark C Chen; Edwin G Fischer; Ekkehard M Kasper
Journal:  Surg Neurol Int       Date:  2013-01-18

10.  Postoperative epidural hematoma contributes to delayed upper cord tethering after decompression of Chiari malformation type I.

Authors:  Antonio López-González; Estela Plaza; Francisco Javier Márquez-Rivas
Journal:  Surg Neurol Int       Date:  2014-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.